Vaccine Info

Pediarix Vaccine

Pediarix Vaccine Description

Pediarix contains noninfectious proteins from diphtheria, tetanus, and pertussis bacteria, hepatitis B virus, and inactivated polioviruses.

Pediarix Vaccine Indication

Pediarix is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis and infection caused by all known subtypes of hepatitis B virus and poliomyelitis.

Pediarix Vaccine Dosage

Pediarix is approved for use as a three-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. Pediarix may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).

Pediarix Vaccine News

June 2, 2020 - COVID-19 Impact on Global Human Vaccines Market Size, Shares, Trends, Demands, Types, Applications & Key Industry Players - Sanofi Pasteur, Merck, Pfizer, AstraZeneca, Valneva, GSK, Seqirus

September 17, 2019 - Merck HepB vaccine shortage extended through mid-2020

Pediarix Clinical Trials

Clinical Trial NCT00146835: Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine

Clinical Trial NCT00133445Pentavalent DTaP-Hep B-IPV

The purpose of this study is to evaluate the safety of administering a combination vaccine (DTaP-HepB-IPV; Pediarix™) to infants at birth, 2 and 6 months compared to the administration of a HepB vaccine at birth and the same combination vaccine at 2, 4, and 6 months of age.

Additionally, researchers will assess the body's antibody response (proteins produced by the body's immune system that help fight infections) following each vaccine dose.

The study will enroll 5 healthy newborns, ages 0-5 days. Participants will be involved in study related procedures for up to 288 days, including blood sample collection and 5 study visits.

Clinical Trial NCT00879827: Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants

The purpose of this study is to evaluate the immune response and reactogenicity of GSK Biologicals' DTPa-HBV-IPV combined pentavalent vaccine and Hib tetanus conjugate vaccine, administered concomitantly as a three-dose primary vaccination course.